Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Pegylated Interferon Alfa-2a Monotherapy Efficacious in Treating Dialysis Patients With Hepatitis C: Presented at AASLD By Maria Bishop BOSTON, MA -- November 5, 2007 -- Pegylated interferon (PEG-IFN) alfa-2a monotherapy is effective in dialysis patients with hepatitis C virus (HCV), demonstrating a sustained virological response (SVR) of 36.8% in this hepatologically compromised patient population, researchers reported here at the 58th Annual Scientific Meeting of the American Association for the Study of Liver Disease (AASLD). PEG IFN alfa-2a, due to its limited excretion (< 10%) appears to be the preferred treatment of haemodialysis patients, despite serious side effects, noted lead author Reinhart Zachoval, MD, Head of Ambulatory Hepatological Care, Medical Clinic 2, Ludwig - Maximilians University (LMU), Grosshadern, Munich, Germany. Dr. Zachoval led an open, prospective multicentre study of 38 haemodialysis patients (23 male) with chronic hepatitis C to evaluate the rate of SVR after 48 weeks of PEG-IFN alfa-2a monotherapy. Patients received 135 ug of PEF-IFN alfa-2a per week at the end of their dialysis procedures for 24 weeks. If patients achieved a decline of HCV ribonucleic acid (RNA) greater than 2 log, therapy was continued for a total of 48 weeks. In a subgroup of 11 patients, results from a dose of 180 ug of the therapy were recorded. SVR was observed in 14 of the 38 patients (36.8%). Seventeen patients were non-responders, and 7 patients showed a relapse of viremia. Repeated dosing at both dose levels resulted in constant drug levels in patients undergoing haemodialysis. A high rate of severe side effects was also shown, however, and 8 patients discontinued the trial due to serious adverse events, including death (myocardial infarction), massive retinal arterial embolisation, grand mal seizures, instable angina, pneumonia, and massive diabetic foot syndrome. While the drug demonstrated good efficacy, the high rate of side effects in this study therefore necessitates meticulous patient selection in these often comorbid individuals, concluded Dr. Zachoval. This trial was sponsored by Roche Pharma, Grenzach, Germany. [Presentation title: PEG-IFN alfa-2a Monotherapy in Dialysis Patients Infected With HCV. Abstract 328] E-mail this page to a friend or colleague! To print, use this version